The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial

dc.contributor.authorAlexea, Octavian
dc.contributor.authorBacarea, Vladimir
dc.contributor.authorPiqué i Clusella, Núria
dc.date.accessioned2020-07-17T07:33:54Z
dc.date.available2020-07-17T07:33:54Z
dc.date.issued2016-06-01
dc.date.updated2020-07-17T07:33:54Z
dc.description.abstractBackground: A medical device containing the film-forming agent reticulated protein and a prebiotic mixture of vegetable oligo- and polysaccharides has been developed, recently receiving European approval as MED class III for the treatment of chronic/functional or recidivant diarrhoea due to different causes including irritable bowel syndrome (IBS). In the present paper, we evaluate a protein preparation containing these components in comparison with placebo in adult patients with diarrhoea-predominant IBS. Methods: In a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial, patients were randomly assigned to receive the combination of oligo- and polysaccharides and reticulated protein and placebo (four oral tablets/day for 56 days). Demographic, clinical and quality of life characteristics and presence and intensity of abdominal pain and flatulence (seven-point Likert scale) were assessed at three study visits (baseline and at 28 and 56 days). Stool emissions were recorded on the diary card using the seven-point Bristol Stool Scale. Results: A total of 128 patients were randomised to receive either tablets containing the combination (n = 63) or placebo (n = 65). Treatment with oligo- and polysaccharides and reticulated protein was safe and well tolerated. A significant improvement in symptoms across the study was observed in patients treated with oligo- and polysaccharides and reticulated protein between visit 2 and visit 3 in abdominal pain (p = 0.0167) and flatulence (p = 0.0373). We also detected a statistically significant increase in the quality of life of patients receiving the active treatment from baseline to visit 3 (p < 0.0001). Conclusions: Treatment with oligo- and polysaccharides and reticulated protein is safe, improving IBS symptoms and quality of life of patients with diarrhoea-predominant IBS. Keywords: Irritable bowel syndrome; abdominal pain; efficacy; flatulence; mucosal protectors; quality of life; reticulated protein; stools; vegetable oligo-saccharides; vegetable polysaccharides.
dc.format.extent11 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec700960
dc.identifier.issn2050-6406
dc.identifier.pmid27403313
dc.identifier.urihttps://hdl.handle.net/2445/168841
dc.language.isoeng
dc.publisherSAGE Publications
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1177/2050640615615050
dc.relation.ispartofUnited European Gastroenterology Journal, 2016, vol. 4, num. 3, p. 455-465
dc.relation.urihttps://doi.org/10.1177/2050640615615050
dc.rights(c) Alexea, Octavian et al., 2016
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Biologia, Sanitat i Medi Ambient)
dc.subject.classificationSíndrome de l'intestí irritable
dc.subject.classificationPolisacàrids
dc.subject.otherIrritable colon
dc.subject.otherPolysaccharides
dc.titleThe combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
700960.pdf
Mida:
866.49 KB
Format:
Adobe Portable Document Format